癌症免疫疗法的嵌合抗原受体：最新研究与未来展望

爱康得

Chimericantigen receptor for adoptiveimmunotherapy of cancer: latest research andfutureprospect

癌症免疫疗法的嵌合抗原受体：最新研究与未来展望

Abstract:

Chimeric antigen receptors (CARs) arerecombinant receptors that combine the specificity of an antigen-specificantibody with the T-cell’s activating functions. Initial clinical trials ofgenetically engineered CAR T cells have significantly raised the profile of Tcell therapy, and great efforts have been made to improve this approach. Inthis review, we provide a structural overview of the development of CARtechnology and highlight areas that requirefurther refinement. We also discusscritical issues related to CAR therapy, including the optimization of CAR Tcells, the route of administration, CAR toxicity and the blocking of inhibitorymolecules.

摘要：

和大家分享一下老外的一篇关于CAR-T的综述，这份文件详细的叙述了嵌合抗原受体技术及其结构的演化过程，同时也讨论了嵌合抗原受体T细胞的治疗的关键因素，包括CAR-T细胞的优化，给药途径，细胞毒性以及在未来和免疫检查点分子合用的可能性等等。总之好文一份 ，欢迎大家下载哦